Boston Scientific Acquires Obsidio For Undisclosed Terms
(RTTNews) - Medical technology company Boston Scientific Corp. (BSX) announced Monday the acquisition of privately-held company Obsidio, Inc. that has developed the Gel Embolic Material (GEM) technology used for embolization of blood vessels in the peripheral vasculature.
The transaction is expected to be immaterial to Boston Scientific's GAAP and adjusted earnings per share in 2022. Specific terms of the transaction have not been disclosed.
Recently cleared by the U.S. Food and Drug Administration (FDA), the GEM technology is a semi-solid, proprietary material packaged in a ready-to-use form, thus reducing the preparation time required for many embolization procedures.
For More Such Health News, visit rttnews.com
read more
Boston Scientific Boosts FY24 Outlook - Update
While reporting financial results for the second quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and sales growth guidance for the full-year 2024.
RTTNews
|
il y a 154
Boston Scientific To Acquire Silk Road Medical For $27.50/share In Deal Valued At About $1.16 Bln
Medical device company Boston Scientific Corp. (BSX) announced Tuesday it has entered into a definitive agreement to acquire smaller peer Silk Road Medical, Inc. (SILK) for $27.50 per share, reflecting an enterprise value of approximately $1.16 billion.
RTTNews
|
il y a 190
Boston Scientific Boosts FY24 Outlook - Update
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024.
RTTNews
|
il y a 245
Boston Scientific Says FTC Issues Second Request Amid Boston Scientific And Axonics Merge Review
Boston Scientific Corp. (BSX) revealed Thursday in a Form 8-K filing with the U.S. Securities and Exchange Commission that the company and Axonics each received a request for additional information from the U.S. Federal Trade Commission (FTC) in connection with the FTC's review of the merger.
RTTNews
|
il y a 265
Boston Scientific To Acquire Axonics For $71/shr In All-cash Deal Valued At About $3.7 Bln
Medical technology company Boston Scientific Corp. (BSX) announced Monday it has entered into a definitive agreement to acquire peer Axonics, Inc. (AXNX) for $71 per share in an all-cash deal valued at approximately $3.7 billion.
RTTNews
|
il y a 352
Boston Scientific To Acquire Relievant Medsystems
Medical technology company Boston Scientific Corp. (BSX) announced Tuesday it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately-held peer. The transaction includes an upfront cash payment of $850 million and undisclosed additional contingent payments based on sales performance over the next three years.
RTTNews
|
il y a 463
Boston Scientific Boosts FY23 Adj. EPS, Sales Growth Outlook - Update
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2023.
RTTNews
|
il y a 609
Nevro And Boston Scientific Reach $85 Mln Settlement Of Ongoing Intellectual Property Litigations
Medical device makers Nevro Corp. (NVRO) and Boston Scientific Corp. (BSX) announced Monday that they have reached a settlement in all their ongoing intellectual property litigations, including a net payment from Boston Scientific to Nevro of $85 million.
RTTNews
|
il y a 877
